J2327 HCPCS code: Injection, risankizumab-rzaa, intravenous, 1 mg
J2327 is the HCPCS Level II code for injection, risankizumab-rzaa, intravenous, 1 mg. In 2024 Medicare paid an average of $11.22 per service for J2327 across 2,874,047 services. Its Medicare coverage code is C (Carrier judgment): Coverage is decided by the Medicare contractor (MAC) case by case. The NCCI unit limit is 1200 per day on DME suppliers. Medicare volume rose 93% from 2023 to 2024 (1,490,899 to 2,874,047 services). In 2024, about 1,804 clinicians billed Medicare for J2327 for 1,965 beneficiaries; Florida, Texas, California accounted for 27% of services.
Code details
| Field | Value |
|---|---|
| Section | J codes — Drugs administered other than oral method |
| Coverage code | C — Carrier judgment |
| Pricing indicator | 51 — Drug or biological (priced per ASP/average sales price rules) |
| BETOS category | O1E — Other drugs |
| Added | 2023-01-01 |
| Last action effective | 2023-01-01 |
Who bills J2327 (2024)
| Measure | Value |
|---|---|
| Clinicians billing (by place of service) | 1,804 |
| Medicare beneficiaries | 1,965 |
| States with claims | 37 |
| Share of services in top 3 states (Florida, Texas, California) | 27% |
Counts only. Supplier and clinician names, contact lists and state-by-state detail are in Caduvo.
Medicare utilization for J2327, 2023–2024
| Year | Services | Beneficiaries | Avg. allowed | Avg. paid |
|---|---|---|---|---|
| 2023 | 1,490,899 | 1,143 | $14.51 | $11.56 |
| 2024 | 2,874,047 | 1,965 | $14.09 | $11.22 |
States with the most J2327 services (2024)
| State | Services | Avg. paid |
|---|---|---|
| Florida | 331,711 | $11.08 |
| Texas | 263,620 | $10.75 |
| California | 161,708 | $11.49 |
| New York | 136,517 | $11.29 |
| Illinois | 135,304 | $11.45 |
NCCI unit limits (MUE)
| Claim type | Max units per day | Rationale |
|---|---|---|
| DME suppliers | 1200 | Prescribing Information |
| outpatient hospital claims | 1200 | Prescribing Information |
| practitioner claims | 1200 | Prescribing Information |
What changed for J2327
- 2023-01-01: J2327 added to HCPCS Level II
- Next scheduled CMS quarterly update (HCPCS and DMEPOS fee schedule): 2027-01-01
Frequently asked questions
What is HCPCS code J2327?
J2327 is the HCPCS Level II code for injection, risankizumab-rzaa, intravenous, 1 mg. Short descriptor: "Inj risankizumab-rzaa 1 mg".
How much does Medicare pay for J2327?
In 2024, the average Medicare payment was $11.22 per service (average allowed $14.09).
Does Medicare cover J2327?
Coverage code C — Carrier judgment. Coverage is decided by the Medicare contractor (MAC) case by case.
How many units of J2327 can be billed per day?
1200 on DME suppliers; 1200 on outpatient hospital claims; 1200 on practitioner claims (NCCI medically unlikely edits).
Related J23 codes
- J2300 — Injection, nalbuphine hydrochloride, per 10 mg
- J2305 — Injection, nitroglycerin, 5 mg
- J2310 — Injection, naloxone hydrochloride, per 1 mg
- J2311 — Injection, naloxone hydrochloride (zimhi), 1 mg
- J2312 — Injection, naloxone hydrochloride, not otherwise specified, 0.01 mg
- J2313 — Injection, naloxone hydrochloride (zimhi), 0.01 mg
- J2315 — Injection, naltrexone, depot form, 1 mg
- J2320 — Injection, nandrolone decanoate, up to 50 mg
- J2323 — Injection, natalizumab, 1 mg
- J2325 — Injection, nesiritide, 0.1 mg
- J2326 — Injection, nusinersen, 0.1 mg
- J2329 — Injection, ublituximab-xiiy, 1mg
Building a device that would bill under a code like this? Caduvo matches a device description to HCPCS/CPT codes, Medicare coverage and payment, and the FDA pathway in one report.
Next steps
- Run a reimbursement report for a device billed under J2327
- Watch J2327 for fee, coverage and descriptor changes
- Build a full Medicare revenue model for J2327
Sources: CMS HCPCS Level II release October 2026; CMS DMEPOS fee schedule; CMS NCCI MUE tables; CMS Medicare utilization (physician and DME supplier files); CMS Medicare Coverage Database articles. Fees are Medicare allowables, not commercial rates. Not billing or legal advice.